Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmunovant Inc

Immunovant Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
37.04 USD 1.33 ( 3.72%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1710315
Market Cap
4129.23M

Momentum Score

…

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
35.52
Low
37.59
High
52 Week Price Range
18.16
Low
45.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing therapies that lower pathogenic IgG by targeting the neonatal Fc receptor (FcRn) to treat autoimmune and other antibody-mediated diseases. Long-term growth drivers include progress of its clinical-stage pipeline, regulatory milestones, potential commercial launches in unmet autoimmune indications, and partnering or licensing opportunities, which may benefit investors seeking exposure to mechanism-based immunology programs.

The most important investment risks are clinical and regulatory failure, competition from other FcRn inhibitors and alternative immune therapies, plus funding and execution risk typical for development-stage biotech.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
35.71
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-44.51%
Net Debt
-375.31M
ROCE
-54.74%
Diluted EPS TTM
-1.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -210.95M -156.81M -107.79M -66.29M -0.00M
Net income -210.96M -156.73M -107.43M -66.39M -0.00M
Selling general administrative 48.02M 54.23M 39.51M 18.15M 2.69M
Reconciled depreciation 0.19M 0.13M 0.07M 0.02M -
Ebit -198.47M -156.16M -107.79M -65.67M -0.00M
Ebitda -198.28M -156.03M -107.72M -65.64M -0.00M
Depreciation and amortization 0.19M 0.13M 0.07M 0.02M -
Non operating income net other -0.25M -0.78M 0.33M - -
Operating income -198.47M -156.16M -107.79M -65.67M -0.00M
Other operating expenses 208.28M 156.03M 108.12M 66.08M 0.00M
Interest expense 12.48M 0.66M 0.00M 0.62M 0.00M
Tax provision 0.01M -0.08M -0.36M 0.10M -
Interest income 7.58M - - 0.62M -
Net interest income 7.58M - 0.00M -0.62M -
Non recurring 10.00M - - - -
Income tax expense 0.01M -0.08M -0.36M 0.10M 0.02M
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 208.28M 156.03M 108.12M 66.08M 0.00M
Total other income expense net -12.48M -0.66M 0.33M -0.62M -0.16M
Net income from continuing ops -210.96M -156.73M -107.43M -66.39M -28.60M
Net income applicable to common shares -210.96M -156.73M -107.43M -66.39M -28.60M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 405.84M 515.56M 412.49M 109.39M 0.41M
Other current assets 26.92M 6.25M 8.31M 5.46M 0.08M
Total liab 43.34M 45.74M 21.01M 15.32M 0.38M
Total stockholder equity 362.49M 469.82M 391.48M 94.07M 0.02M
Deferred long term liab - - - 0.25M 1.20M
Other current liab 40.77M 24.75M 15.16M 14.13M 0.08M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -566.35M -355.39M -198.66M -91.23M -0.00M
Other assets - - - 0.25M 1.20M
Cash 376.53M 493.82M 400.15M 100.57M 0.33M
Total current liabilities 43.30M 44.52M 18.77M 15.32M 0.38M
Net debt -375.31M -491.45M -396.73M -100.57M -0.03M
Short term debt 1.17M 1.15M 1.18M - 0.30M
Short long term debt - - - - 0.30M
Short long term debt total 1.22M 2.36M 3.42M - 0.30M
Other stockholder equity 927.98M 824.80M 590.42M 185.31M 0.02M
Property plant equipment 0.33M 0.33M 0.20M 0.07M 0.05M
Total current assets 404.33M 512.93M 409.01M 109.08M 0.33M
Net tangible assets 362.49M 469.82M 391.48M 94.07M 7.34M
Net receivables 0.89M 12.86M 0.55M 3.04M 2.96M
Accounts payable 1.35M 18.63M 2.43M 1.19M 0.21M
Accumulated other comprehensive income 0.85M 0.40M -0.30M -0.02M -
Common stock total equity 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings total equity -566.35M -355.39M -198.66M - -
Non currrent assets other - - - 0.25M 0.08M
Non current assets total 1.50M 2.63M 3.48M 0.31M 0.08M
Capital lease obligations 1.22M 2.36M 3.42M - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.20M -0.25M -0.21M -0.03M -
Change to liabilities -1.40M 25.90M 5.72M 0.97M -0.93M
Total cashflows from investing activities -0.20M -0.25M -0.21M -0.03M -0.05M
Net borrowings - - -3.19M 37.91M 37.91M
Total cash from financing activities 70.89M 200.13M 383.11M 146.97M 0.33M
Change to operating activities - 10.61M 3.83M 3.83M -0.47M
Net income -210.96M -156.73M -107.43M -66.39M -0.00M
Change in cash -117.28M 93.67M 299.57M 93.59M 0.33M
Begin period cash flow 493.82M 400.15M 100.57M 6.99M -
End period cash flow 376.53M 493.82M 400.15M 100.57M 0.33M
Total cash from operating activities -188.19M -106.11M -83.33M -53.36M -28.55M
Issuance of capital stock 70.50M 0.00M 319.78M 0.00M -
Depreciation 0.19M 0.13M 0.07M 0.02M 0.01M
Change to account receivables 11.76M -11.63M -0.51M -11.63M -11.63M
Sale purchase of stock 70.89M 200.00M 385.21M 0.00M 0.03M
Other cashflows from financing activities 0.39M 200.13M 66.52M 151.97M 0.30M
Change to netincome 32.30M 34.24M 18.54M 6.58M 1.49M
Capital expenditures 0.20M 0.25M 0.21M 0.03M 0.05M
Change receivables 11.76M -11.63M - - -
Cash flows other operating -20.09M 1.98M -0.22M - -
Cash and cash equivalents changes -117.50M 93.76M 299.57M - -
Change in working capital -10.85M 15.14M 4.57M 4.81M 0.00M
Stock based compensation 32.30M 34.24M 18.82M 6.96M -
Other non cash items 1.13M 1.11M 0.93M 1.24M -
Free cash flow -188.39M -106.37M -83.54M -53.39M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
IMVT
Immunovant Inc		 1.33
3.72%		 37.04 - - - 6.28 -14.12
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Immunovant Inc

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

320 West 37th Street, New York, NY, United States, 10018

(917) 580-3099

https://immunovant.com

164

Name Title Year Born
Dr. Frank M. Torti M.B.A., M.D., MBA Exec. Chairperson of the Board 1979
Dr. Peter Salzmann M.B.A., M.D. CEO & Director 1968
Ms. Eva Renee Barnett M.B.A. Chief Financial Officer 1980
Dr. William L. Macias M.D., Ph.D. Chief Medical Officer 1958
Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer 1971
Dr. Chau Cheng M.B.A., Ph.D. VP of Investor Relations NA
Mr. Mark S. Levine Chief Legal Officer & Corp. Sec. 1973
Ms. Lauren Schrier M.B.A. VP of Marketing NA
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board 1979
Dr. Peter Salzmann M.B.A., M.D. CEO & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…